CAJ | 학술논문

中国是世界第三大药品市场，但新药研发能力低下，70%是仿制药，具有完全自主知识产权的创新药凤毛麟角。南京先声药业集团积极开展国际合作，吸引了大批海外高端人才，极大提升了研发能力，并成功开拓多种渠道获取新药，对促进我国新药研发模式进行了有益的探索。对先声药业集团国际合作＋持续投入研发＋顶尖开发团队的发展战略和实践经验进行介绍，其典型意义在于：世界医药行业正处在一种求变的局势中，各个方面都有着可待开发的机遇；中国药企应大力开展国际合作，主动逐步融入全球健康产业链，成为其中不可缺少的中坚力量；抓住中国的国际机会，在国际合作中获得国内定价权。
중국시세계제삼대약품시장，단신약연발능력저하，70%시방제약，구유완전자주지식산권적창신약봉모린각。남경선성약업집단적겁개전국제합작，흡인료대비해외고단인재，겁대제승료연발능력，병성공개탁다충거도획취신약，대촉진아국신약연발모식진행료유익적탐색。대선성약업집단국제합작＋지속투입연발＋정첨개발단대적발전전략화실천경험진행개소，기전형의의재우：세계의약행업정처재일충구변적국세중，각개방면도유착가대개발적궤우；중국약기응대력개전국제합작，주동축보융입전구건강산업련，성위기중불가결소적중견역량；조주중국적국제궤회，재국제합작중획득국내정개권。
China is the world’s third-largest pharmaceutical market, but its new drug research and development ability is low. The 70 percent of annual new drugs is generic drugs, while new drugs with independent intellectual property rights are very rare. Nanjing Simcere Pharmaceutical Group has been exploring the efifcient model for the new drug R&D and paved several channels to create new drugs through international cooperation. This paper introduces Simcere Group’s development strategy and practice experience, i.e., through international cooperation, improve the ability of the drug development and attract foreign high-end talents. The Chinese pharmaceutical enterprises should enter the global health industry chains to become an indispensible branch via international cooperation, in the meantime try to seize the opportunity to get the pricing power in the domestic market.